Propensity score matched comparison of SBRT versus IMRT for the treatment of localized prostate cancer
· PDF 檔案ORIGINAL RESEARCH Propensity score matched comparison of SBRT versus IMRT for the treatment of localized prostate cancer Caspian Oliai1 & Matthew Bernetich1 & Luther Brady1,2 & Jun Yang1,2 & Alexandra Hanlon3 & John Lamond1 & Steven Arrigo1 & Michael Good1 &
The Comparison of Stereotactic Body Radiation Therapy and Intensity-Modulated Radiation Therapy for Prostate Cancer …
· PDF 檔案SBRT and IMRT for men with organ confined prostate cancer treated between 2007 through 2012 utilizing the 2015 NCCN risk stratification guidelines in a larger database from our institution.
The Comparison of Stereotactic Body Radiation Therapy …
There was no significant difference in FFBF between SBRT vs. IMRT (p=0.46) with 6 year actuarial FFBF of 91.9% for SBRT and 88.9% for IMRT. Multivariable analysis revealed only the NCCN risk stratification to be significant predictor for FFBF (p=0.04). 4 year actuarial FFBF by NCCN risk stratification was 100% very low risk, 100% low risk, 96.5% intermediate risk, 94.5% high risk, and 72.7%
Phase III IGRT and SBRT vs IGRT and Hypofractionated …
SBRT is experimental for treating this type of cancer. In certain regions, there are authored local coverage determinations that identify SBRT as a routine care service for this disease. SBRT uses special equipment to position a participant and precisely deliver radiation to tumors in the body.
Phase III IGRT and SBRT vs IGRT and Hypofractionated …
III. To determine if SBRT (5 fractions of 7.25 Gy) is superior to hypofractionated IMRT (28 fractions of 2.5 Gy) as measured by biochemical failure, overall survival, local failure, prostate cancer specific survival, and distant metastases. IV.
Proton-Beam vs Intensity-Modulated Radiation Therapy
External-beam radiation is a highly effective curative treatment option for men with localized prostate cancer.[1,2] Over the past several decades, efforts have been made to improve the “therapeutic ratio” of radiation by increasing dose to improve cure rates without causing a substantial increase in side effects. Due to its potential to create superior dose distributions, proton therapy
Comparative Toxicities, Cost of 3 RTs for Prostate Cancer
For patients, the mean out-of-pocket costs — $1015 for receiving SBRT vs $1560 for IMRT — were benefit associated with proton radiation compared with IMRT for prostate cancer, with results
Exploring Value From the Patient’s Perspective Between …
· METHODS AND MATERIALS: Patients with localized prostate cancer treated with stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), or high-dose-rate (HDR) brachytherapy between 2008 and 2014 with at least 1 year of
Stereotactic Body Radiotherapy (SBRT) for Prostate Cancer: Practical Considerations for Treatment Planning
· PDF 檔案Stereotactic Body Radiotherapy (SBRT) for Prostate Cancer: Practical Considerations for Treatment Planning Minsong Cao, Ph.D. Department of Radiation Oncology Outline of Presentation • Introduction • Simulation and immobilization • Treatment planning process
NF-1 and Prostate Cancer
· I don’t think I understand the SBRT vs IMRT argument. SBRT is just a conformal form of IMRT. If you turn on enough isodose lines in relative (as opposed to absolute) dose they don’t look that much different from prostate only with conventional IMRT aside from
Frontiers
In fact this exact result was reported by Zelefsky et al. in the comparison of long term outcomes between prostate IMRT vs. brachytherapy, where the shorter term lower PSA nadir associated with brachytherapy vs. IMRT seen within the first 4 years (0.1 vs. 0.6).
NRG GU005
Phase III IGRT and SBRT Vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer Location: Bemidji Clinic, Bismarck Region, Fargo Region, Sioux Falls Region
CYBERKNIFE SBRT FOR THE TREATMENT OF PROSTATE CANCER: 5 VS…
· PDF 檔案organ confined prostate cancer with either IMRT (n=120) or SBRT (n=150) • Charts were abstracted for pretreatment and treatment factors as well as outcome and toxicity • NCCN Risk Group Guidelines V. 2.2015 were used to stratify patients into Very Low